Inbrija, the first inhaled levodopa, has been made available by Acorda Therapeutics for the intermittent treatment of OFF episodes in patients with Parkinson disease treated with carbidopa/levodopa.
Inbrija capsules are for oral inhalation and should only be used with the Inbrija inhaler; each capsule contains 42mg of levodopa in a dry powder formulation. Treatment is administered when symptoms of an OFF period start to return.
As there is a risk of bronchospasm, Inbrija is not recommended for patients with asthma, chronic obstructive pulmonary disease (COPD), or other chronic underlying lung disease. Cough was reported as the most frequent adverse reaction following administration.
Inbrija is supplied in cartons containing 60 and 92 capsules; each carton contains an Inbrija inhaler. The product will be available through a network of specialty pharmacies. A prescription request form to initiate treatment for patients can be found here.
For more information call (800) 367-5109 or visit Inbrija.com.
This article originally appeared on MPR